{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:25:08Z","timestamp":1780367108997,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.semarthrit.2019.11.002","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T11:19:04Z","timestamp":1573471144000},"page":"303-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials"],"prefix":"10.1016","volume":"50","author":[{"given":"Sarah","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Gaffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2019.11.002_bib0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.23607","article-title":"Gout, hyperuricemia and crystal-associated disease network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout","volume":"7","author":"Bursill","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40271-016-0184-x","article-title":"What outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions","volume":"10","author":"Tatlock","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0003","article-title":"A qualitative study exploring perceptions of patients with gout","author":"Seow","year":"2018","journal-title":"Clin Nurs Res"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RHU.0b013e318204a8f9","article-title":"The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach","volume":"17","author":"Lindsay","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0005","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0006","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief report: validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0007","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","article-title":"Developing a provisional definition of flare in patients with established gout","volume":"64","author":"Gaffo","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0008","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0009","series-title":"Cochrane handbook for systematic reviews of interventions 2011","year":"2018"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000051263","article-title":"Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials","volume":"12","author":"Oremus","year":"2001","journal-title":"Dement Geriatr Cognit Disord"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41927-019-0075-6","article-title":"The challenges of gout flare reporting: mapping flares during a randomized controlled trial","volume":"3","author":"Teoh","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0012","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s40674-015-0014-7","article-title":"Outcome measures for gout clinical trials: a summary of progress","volume":"1","author":"de Lautour","year":"2015","journal-title":"Curr Treat Option Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0013","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3899\/jrheum.170911","article-title":"Variability in the reporting of serum urate and flares in gout clinical trials: need for minimum reporting requirements","volume":"45","author":"Stamp","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0014","first-page":"290","article-title":"Patient perception of gout flares as a measure of outcome: results from an international study","volume":"68","author":"Gaffo","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0015","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0016","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0017","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2011-200156","article-title":"Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial","volume":"71","author":"Dalbeth","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0018","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.33412","article-title":"Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0019","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/acr.21690","article-title":"Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0021","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3899\/jrheum.131226","article-title":"Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study","volume":"41","author":"Sundy","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0022","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0023","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/MJT.0000000000000284","article-title":"Combination therapies of diacerein and febuxostat inhibit il-1beta responses and improve clinical symptoms in patients with refractory gout","volume":"24","author":"Yu","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0024","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0025","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0026","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase ii randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0027","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0029","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the focus efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0030","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the confirms trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0031","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0032","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0033","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2013-205036","article-title":"Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0034","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","article-title":"An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia","volume":"17","author":"Huang","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/imj.12661","article-title":"Comprehensive dietary education in treated gout patients does not further improve serum urate","volume":"45","author":"Holland","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0036","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0037","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0038","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B 5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0039","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational clear 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0040","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase iii clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0041","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0042","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0043","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0044","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6mg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0045","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatol (Oxf)"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0046","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0047","first-page":"1","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: findings from two phase II trials","volume":"18","author":"Fitz-Patrick","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0048","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","article-title":"Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study","volume":"20","author":"Gunawardhana","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0049","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.40685","article-title":"Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: phase III placebo-controlled study","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0050","first-page":"1623","article-title":"The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia","volume":"31","author":"Wang","year":"2018","journal-title":"Pak J Pharm Sci"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0051","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2019.11.002_bib0052","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s13063-018-2917-8","article-title":"\u201cYellow-dragon wonderful-seed formula\u201d for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial","volume":"19","author":"Yu","year":"2018","journal-title":"Trials"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219306821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219306821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:01:10Z","timestamp":1758733270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017219306821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0049017219306821"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}